Abstract:Objective To study dendritic cells(DC)precursors that were mobilized into the pe- ripheral blood by injection of macrophage inflammation protein-1α(MIP-1α)and the anti-tumor effects induced by MIP-1αmobilized DC vaccine expressing tumor antigen in vivo.Methods 615 mice were in- jected with MIP-1αvia the tail vein.B220~-CD11c~+cells were sorted from the peripheral blood mononu- clear cells(MNCs)by FACS.The quantitive change of B220~-CD11c~+cells were compared among MNCs.Freshly isolated B220~-CD11c~+cells and B220~-CD11c~+cells cultured with mouse granulocyte- macrophage colony-stimulating factor(mGM-CSF),interleukin 4(IL-4),and mouse tumor necrosis factor-α(mTNF-α)were analyzed by phenotype analysis,and mixed lymphocyte reaction(MLR).For adenovi- ral(Ad)-mediated gene transduetion,cultured B220~-CD11c~+cells were incubated with Ad-melanoma antigen gene-3.B220~-CD11c~+cells pulsed mouse forestomach carcinoma cells(MFC)tumor lysate was used as control.To establish the solid tumor model,groups of 615 mice were injected with MFC cells sub- cutaneously in the abodminal wall.DC vaccines were immunized after the challenge of MFC cells,then the tumor size and the survival of mice which could detect the anti-tumor effects of DC vaccines were ob- served.Results B220~-CD11c~+cells were increased in the circulation 8 h after MIP-1αinjection, then gradually reached a peak level 48 h after injection,accounting for(13.68±0.95)% among MNCs. Freshly isolated B220~-CD11c~+cells did not show the characters of mature DC,while cultured B220~- CD11c~+cells were phenotyically identical to typical DC and gained the capacity to stimulate allogeneie T cells.These MIP-1αmobilized DCs were transduced with Ad-MAGE-3,which were prepared for DC vac- cines expressing tumor antigen.Five days after the challenge of MFC cells,mice were subsequently injected with DC vaccines.The.tumor size in the experimental group was much smaller than that in the control groups 27 days after the challenge.Kaplan-Meier survival curves revealed that the survival of the mice in the experimental group was much longer than that in the control groups(P<0.01).Conclusion B220~- CD11c~+DC precursors were rapidly accumulated in the peripheral blood after injection of MIP-1αin mice,which could further differentiate into mature DCs.These MIP-1αmobilized DCs,when transduced with MAGE-3 gene,could generate therapeutic anti-tumor effects on MFC cells loading mice in vivo.The efficiency of anti-tumor immunity induced by MIP-1αmobilized DCs expressing tumor antigen were much more potent than MIP-1αmobilized DCs pulsed MFC cells tumor lysate.

GENETICALLY MODIFIED DENDRITIC CELLS INDUCED SPECIFIC CYTOTOXITY AGAINST HUMAN HCC CELLS IN VITRO

[Study of the Cytotoxity Against Human Hepatocellular Carcinoma Cells Induced by the MAGE-1 Gene Modified Dendritic Cells].

In Vitro Induction of Specific Anti-Tumoral Immunity Against Hepatocellular Carcinoma by Using Murine Interleukin-12 Gene-Modified Dendritic Cells

The Induction of Specific Anti-Tumor Immunity Against Hepatocellular Carcinoma in Vitro by Using Murine Interleukin-12 Gene-Modified Dendritic Cells

Study on the Immune Response Induced by Hbcag Gene-Modified Dendritic Cells in Hepatitis B Virus Transgenic Mice

Dendritic cells transfected with tumor total RNA induce specific immune responses against hepatocellular carcinoma in vitro

Induction of Cytotoxic T Lymphocytes from the Peripheral Blood of a Hepatocellular Carcinoma Patient Using a MAGE-1 Peptide (NYKCRFPEI) in Vitro

Induction of Cytotoxic T Lymphocytes from the Peripheral Blood of A Hepatocellular Carcinoma Patient Using Melanoma Antigen-1 (Mage-1) Peptide

Antitumor Effect of Immunizations with Fusions of Dendritic and Hepatocellular Carcinoma Cells in Mice

Alpha-fetoprotein and IL-18 Gene-Modified Dendritic Cells-Induced CTL Response Against Hepatocellular Carcinoma Cells

Experimental Study of Β-Gc Combined with HBsAg Gene-Modified Dendritic Cell-Based Tumor Vaccine to Hepatocellular Carcinoma by Different Immune Ways

Use of Interferon Γ Gene Modified Dendritic Cells in Immunotherapy for Hepatic Cancer

Anti-gastric carcinoma efficacy of gene modified dendritic cell vaccine recruited by macrophage inflammation protein-1

[388] PEG10 IS OVEREXPRESSED IN HEPATOCELLULAR CARCINOMA AND IS A POTENTIAL TARGET FOR HEPATOCELLULAR CARCINOMA GENE THERAPHY

Improvement of HBsAg gene-modified dendritic cell-based vaccine efficacy by optimizing immunization method or the application of β-glucosylceramide.

[Application of a Tumor Cell Vaccine Transfected with GM-CSF/IL-2 Fusion Gene for Specific Immunotherapy of Hepatocellular Carcinoma].

Specific Antitumor-Immunity Induced by Mil-12 Gene Modified Dendritic Cells Transfected with Murine Colon Carcinoma RNA

Peptide Derived from MAGE-3 Epitope Induced Cytotoxic T Lymphocytes of Hepatocellular Carcinoma Patient in Vitro

Dendritic Cell Generated from CD34+ Hematopoietic Progenitors Can Be Transfected with Adenovirus Containing Gene of HBsAg and Induce Antigen-Specific Cytotoxic T Cell Responses.

Induction of Specific Cytolytic T Lymphocytes Using Fusions of Hepatocellular Carcinoma (HCC) Patient-Derived Dendritic Cells and Allogeneic HCC Cell Line.

Dendritic Cells Pulsed with Α‐fetoprotein and Mutant P53 Fused Gene Induce Bi‐targeted Cytotoxic T Lymphocyte Response Against Hepatic Carcinoma